Invitation to Participate in a Study on Post-Acute Infection Syndromes (PAIS)

We are pleased to share an opportunity for individuals affected by ME/CFS, Post-COVID, and other conditions triggered by infections to participate in a research study.

Our colleagues at the Austrian Association of ME/CFS, in collaboration with the Medical University of Vienna, are conducting a study on Post-Acute Infection Syndromes (PAIS).

While the study is primarily focused on patients in Austria, Germany, and Switzerland, it is open to participants across Europe. The associated questionnaire is available in both English and German to accommodate a wider audience.

The study aims to collect information on the diagnostic journey of individuals who develop symptoms following certain triggers. These symptoms may often be diffuse and seemingly unrelated. The questionnaire enquires about changes in daily life, the diagnostic process, medical care, and attempts at treatment.

The study’s target group includes both diagnosed and undiagnosed individuals who have experienced symptoms for more than 3 months. The research team is also interested in the experiences of people who have recovered.

Target Group:
Adults with PAIS, including both diagnosed and undiagnosed individuals. Duration: The survey is open for at least two months, and participants can pause and resume the questionnaire at any time.

How to Participate:
If you meet the criteria and wish to participate, you can access the survey by following the link below:

https://s2survey.net/pais/

In EMEA, we recognise the importance of data, having completed an extensive pan-European survey and publishing the results [1].

In Austria, there is currently significant momentum in ME/CFS research.
We are pleased to have Austrian representation in the European ME Research Group (EMERG), with Associate Professor Eva Untersmayr-Elsenhuber [2] and Dr Thomas Vogl [3] from the Medical University of Vienna, as well as Johanna Rohrhofer on the committee of Young EMERG [4].


Last Update: November 2024

Return to News